SCHEMBL2315903

SCHEMBL2315903

O=C1c2ccccc2-c2c1cccc2-c1nc2cccnc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.43
CDK2 P24941 1/20 0.43
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
CDK4 P11802 1/20 0.40
CCND2 P30279 1/20 0.40
IDO1 P14902 1/20 0.40
KDM4E B2RXH2 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HSP90AB1 P08238 1/20 0.40
PTPRC P08575 2/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
PTPN13 Q12923 1/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2313325 0.81 KEAP1 (0.39) CDK4CCND2IDO1PTPRCALDH1A1
SCHEMBL3554267 0.80 CDK1 (0.43) CDK1CDK2MKNK1MKNK2FGFR1
SCHEMBL3554269 0.80 CDK1 (0.43) CDK1CDK2MKNK1MKNK2FGFR1
SCHEMBL2314062 0.80 NPC1 (0.57) CDK1CDK2MKNK1MKNK2FGFR1
SCHEMBL2314048 0.77 CDK1 (0.42) CDK1CDK2MKNK1MKNK2FGFR1
SCHEMBL12431584 0.77 PDE5A (0.47) FGFR1FLT1IDO1KDM4ENPSR1
SCHEMBL2312523 0.77 PDE5A (0.60) FGFR1FLT1IDO1KDM4EHSP90AB1
SCHEMBL3338377 0.75 PDE5A (0.59) CDK1CDK2MKNK1MKNK2FGFR1
SCHEMBL15633796 0.75 NPC1 (0.46) CDK1CDK2MKNK1MKNK2FGFR1
SCHEMBL27715989 0.75 HSP90AB1 (0.47) CDK1CDK2MKNK1MKNK2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888579-B1 NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF AVENTIS PHARMA SA (FR) 2011-08-03 EP disclosed
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed
EP-1888579-A2 NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF Aventis Pharma S.A. (FR) 2008-02-20 EP disclosed
WO-2006123061-A2 FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 CDK1 2875/4885CDK2 2439/4885MKNK1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.